TGTX experienced a substantial decline in revenue alongside significantly higher R&D spending, while total assets roughly doubled despite a material reduction in cash reserves.
The company appears to be in a critical transition phase with revenue dropping substantially while R&D expenses grew meaningfully, suggesting either pipeline setbacks or strategic shifts in drug development priorities. The doubling of total assets concurrent with declining cash indicates potential major asset acquisitions or investments that investors should scrutinize closely.
TGTX's financial position shows mixed signals with total assets roughly doubling to $1.1B while cash reserves declined substantially from $179.9M to $79.1M. Operating expenses expanded significantly with R&D costs growing meaningfully and SG&A expenses increasing modestly, even as revenue dropped substantially. The improvement in operating cash flow provides some cushion, but the overall picture suggests a company making major investments or acquisitions while facing revenue headwinds and burning through cash reserves.
Asset base grew 84.1% — expansion through organic growth, acquisitions, or capital deployment.
R&D investment increased 69.9% — signals commitment to future product development, though near-term margin impact.
Current liabilities surged 69.6% — significant near-term obligations; verify ability to meet short-term debt.
Revenue declined 58.4% — significant demand weakness or market share loss warrants investigation.
Cash declined 56% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
SG&A up 50.4% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Debt increased 41.1% — substantial leverage increase; assess whether deployed for growth or covering losses.
Operating cash flow surged 38.9% — exceptional cash generation, highest quality earnings signal.
Interest costs rose 23.8% — monitor debt levels and coverage ratio in rising rate environment.
Liabilities increased 16.9% — monitor debt-to-equity ratio and interest coverage.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →